379 results on '"Arnold, Mark E."'
Search Results
2. Contributors
3. Bioanalytical methods: Technological platforms and method validation
4. Biomarker Assay Validation by Mass Spectrometry
5. Assessment of Survival Kinetics for Emergent Highly Pathogenic Clade 2.3.4.4 H5Nx Avian Influenza Viruses.
6. Biological Matrix Supply Chain Shortages: More Matrices Are Now Rare—the Case for Surrogate Matrices
7. Efficient Bayesian modeling of large lattice data using spectral properties of Laplacian matrix
8. Using stochastic dynamic modelling to estimate the sensitivity of current and alternative surveillance program of Salmonella in conventional broiler production
9. Considerations for drug development biomarker assays in the clinical laboratory
10. Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach
11. Assessing the time taken for a surveillance system to detect a re-emergence of bovine spongiform encephalopathy in cattle
12. Between roost contact is essential for maintenance of European bat lyssavirus type-2 in Myotis daubentonii bat reservoir: ‘The Swarming Hypothesis’
13. Bioanalysis of dried saliva spot (DSS) samples using detergent-assisted sample extraction with UHPLC-MS/MS detection
14. A validated enantioselective LC–MS/MS assay for quantification of a major chiral metabolite of an achiral 11-β-hydroxysteroid-dehydrogenase 1 inhibitor in human plasma: Application to a clinical pharmacokinetic study
15. Quantitation of a PEGylated protein in monkey serum by UHPLC-HRMS using a surrogate disulfide-containing peptide: A new approach to bioanalysis and in vivo stability evaluation of disulfide-rich protein therapeutics
16. Post-pellet-digestion precipitation and solid phase extraction: A practical and efficient workflow to extract surrogate peptides for ultra-high performance liquid chromatography – tandem mass spectrometry bioanalysis of a therapeutic antibody in the low ng/mL range
17. Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC–MS/MS approach: Assay development, validation, and a case study
18. Challenges and solutions in the bioanalysis of BMS-986094 and its metabolites including a highly polar, active nucleoside triphosphate in plasma and tissues using LC–MS/MS
19. A UHPLC–MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma
20. “Center punch” and “whole spot” bioanalysis of apixaban in human dried blood spot samples by UHPLC-MS/MS
21. Development and validation of a liquid chromatography tandem mass spectrometry assay for the quantitation of a protein therapeutic in cynomolgus monkey serum
22. Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma
23. Sensitive and accurate liquid chromatography–tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine
24. Workshop Report: Crystal City VI—Bioanalytical Method Validation for Biomarkers
25. A validated LC–MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma
26. Use of a carboxylesterase inhibitor of phenylmethanesulfonyl fluoride to stabilize epothilone D in rat plasma for a validated UHPLC–MS/MS assay
27. The impact of BCG strains and repeat vaccinations on immunodiagnostic tests in Eurasian badgers (Meles meles)
28. Improved liquid–liquid extraction with inter-well volume replacement dilution workflow and its application to quantify BMS-927711 in rat dried blood spots by UHPLC–MS/MS
29. Bioanalysis of propylparaben and p-hydroxybenzoic acid, and their sulfate conjugates in rat plasma by liquid chromatography–tandem mass spectrometry
30. Application of a stabilizer cocktail of N-ethylmaleimide and phenylmethanesulfonyl fluoride to concurrently stabilize the disulfide and ester containing compounds in a plasma LC–MS/MS assay
31. A rapid, accurate and robust UHPLC–MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies
32. A simplified and completely automated workflow for regulated LC–MS/MS bioanalysis using cap-piercing direct sampling and evaporation-free solid phase extraction
33. A rugged and accurate liquid chromatography–tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma
34. Workshop Report: Crystal City V—Quantitative Bioanalytical Method Validation and Implementation: The 2013 Revised FDA Guidance
35. A sensitive and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine
36. A User-Friendly Robotic Sample Preparation Program for Fully Automated Biological Sample Pipetting and Dilution to Benefit the Regulated Bioanalysis
37. Chapter 11 - Bioanalytical methods: Technological platforms and method validation
38. Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations
39. A rugged and accurate liquid chromatography–tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma
40. A highly sensitive and selective LC–MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies
41. Development and validation of sensitive and selective LC–MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions
42. A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit
43. A sensitive method for the determination of entecavir at picogram per milliliter level in human plasma by solid phase extraction and high-pH LC–MS/MS
44. Identifying, evaluating, and controlling bioanalytical risks resulting from nonuniform matrix ion suppression/enhancement and nonlinear liquid chromatography--mass spectrometry assay response
45. Development and validation of an LC–MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target
46. LC–MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column
47. Reflecting on a decade of metabolite screening and monitoring
48. Sensitivity-based analytical approaches to support human absolute bioavailability studies
49. Strategy of accelerated method development for high-throughput bioanalytical assays using ultra high-performance liquid chromatography coupled with mass spectrometry
50. A Bayesian analysis of a Test and Vaccinate or Remove study to control bovine tuberculosis in badgers (Meles meles)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.